SCHEMBL6727952

SCHEMBL6727952

N#Cc1ccc(-c2cc(NC=O)c(Cl)nn2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 5/20 0.56
MAOB P27338 1/20 0.44
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
ABCB1 P08183 1/20 0.36
ABCG2 Q9UNQ0 1/20 0.36
GSK3B P49841 1/20 0.35
SCN2A Q99250 1/20 0.34
SCN10A Q9Y5Y9 1/20 0.34
SLC22A12 Q96S37 2/20 0.34
GAA P10253 1/20 0.34
EGLN1 Q9GZT9 1/20 0.33
MAPKAPK2 P49137 1/20 0.33
NOTUM Q6P988 1/20 0.33
RHEB Q15382 1/20 0.33
ACP1 P24666 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5899687 0.82 CASP1 (0.51) CASP1MAOB
SCHEMBL5899639 0.82 CASP1 (0.58) CASP1SLC22A12
SCHEMBL5899743 0.82 CASP1 (0.49) CASP1MAOBGABRA1GABRG2GABRB3
SCHEMBL5899723 0.81 CASP1 (0.50) CASP1GSK3BPPARG
SCHEMBL5899753 0.79 CASP1 (0.54) CASP1MAOBGSK3BACP1
SCHEMBL5899707 0.79 CASP1 (0.54) CASP1MAOBKDM1A
SCHEMBL5899797 0.78 CASP1 (0.55) CASP1MAOBGSK3BKDM1A
SCHEMBL5899646 0.77 CASP1 (0.33) CASP1MAOB
SCHEMBL5899710 0.76 CASP1 (0.54) CASP1
SCHEMBL5899784 0.76 MAOB (0.45) MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110725-A1 Pyridazines as interleukin-1beta converting enzyme inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2004-06-10 US claimed
US-6624166-B1 Pharmaceutical compositions containing the compounds; and a method for inhibiting interleukin-1 beta protease activity in a mammal utilizing the compounds and compositions for enzyme inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-09-23 US claimed
US-6121266-A TREATMENT/PROPHYLAXIS OF INFLAMMATORY DISEASES, IMMUNE DISEASES, CANCER VERTEX PHARMACEUTICALS, INC. (US) 2000-09-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110725-A1 Pyridazines as interleukin-1beta converting enzyme inhibitors IL6ST, IL1RN, IL1R1 CASP1 117/4885MAOB 1518/4885GABRA1 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.